{"id":3729,"date":"2025-04-22T16:58:45","date_gmt":"2025-04-22T13:58:45","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3729"},"modified":"2025-05-07T16:13:03","modified_gmt":"2025-05-07T13:13:03","slug":"satellos-sat-3247-phase-2-clinical-study-ready-to-launch","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/satellos-sat-3247-phase-2-clinical-study-ready-to-launch\/","title":{"rendered":"Satellos se pr\u00e9pare \u00e0 lancer l&#039;\u00e9tude clinique de phase 2 du SAT-3247 pour le traitement de la dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos Bioscience, une soci\u00e9t\u00e9 de biotechnologie en phase clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies r\u00e9g\u00e9n\u00e9ratives pour les maladies musculaires, a annonc\u00e9 sur ClinicalTrials.Gov qu&#039;elle se pr\u00e9parait \u00e0 lancer une \u00e9tude clinique de phase 2 sur son principal candidat m\u00e9dicament, SAT-3247, ciblant la dystrophie musculaire de Duchenne (DMD). Il s&#039;agit d&#039;une \u00e9tape importante dans la mission de l&#039;entreprise\u00a0: offrir un traitement r\u00e9volutionnaire aux personnes atteintes de cette maladie g\u00e9n\u00e9tique rare et invalidante.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u00c9tude clinique de phase 2 Satellos SAT-3247<\/h2><nav><ul><li class=\"\"><a href=\"#what-is-sat-3247\">Qu&#039;est-ce que SAT-3247 ?<\/a><\/li><li class=\"\"><a href=\"#why-this-matters-for-duchenne-muscular-dystrophy\">Pourquoi cela est important pour la dystrophie musculaire de Duchenne<\/a><\/li><li class=\"\"><a href=\"#whats-next-for-the-clinical-trial\">Quelle est la prochaine \u00e9tape pour l\u2019essai clinique ?<\/a><\/li><li class=\"\"><a href=\"#a-new-chapter-in-muscle-regeneration\">Un nouveau chapitre dans la r\u00e9g\u00e9n\u00e9ration musculaire<\/a><\/li><li class=\"\"><a href=\"#how-can-my-son-participate-in-the-clinical-trial\">Comment mon fils peut-il participer \u00e0 l\u2019essai clinique de phase 2 SAT-3247\u00a0?<\/a><\/li><li class=\"\"><a href=\"#about-satellos-bioscience\">\u00c0 propos de Satellos Bioscience<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sat-3247\">Qu&#039;est-ce que SAT-3247 ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247 est une petite mol\u00e9cule innovante con\u00e7ue pour restaurer la capacit\u00e9 de l&#039;organisme \u00e0 r\u00e9g\u00e9n\u00e9rer les muscles en ciblant la polarit\u00e9 des cellules souches musculaires. Contrairement aux th\u00e9rapies actuelles contre la dystrophie musculaire (DMD), qui visent principalement \u00e0 ralentir la d\u00e9g\u00e9n\u00e9rescence musculaire, SAT-3247 se concentre sur l&#039;activation des voies naturelles de r\u00e9g\u00e9n\u00e9ration de l&#039;organisme pour reconstruire et r\u00e9parer les tissus musculaires endommag\u00e9s, offrant ainsi une approche potentiellement r\u00e9volutionnaire pour la modification de la maladie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Apprendre encore plus: <a href=\"https:\/\/dmdwarrior.com\/fr\/satellos-sat-3247-stem-cell-approach-may-restore-muscle-regeneration-in-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">L&#039;approche par cellules souches Satellos et SAT-3247 pourrait restaurer la r\u00e9g\u00e9n\u00e9ration musculaire dans la dystrophie musculaire de Duchenne<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-this-matters-for-duchenne-muscular-dystrophy\">Pourquoi cela est important pour la dystrophie musculaire de Duchenne<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">La dystrophie musculaire de Duchenne est une maladie g\u00e9n\u00e9tique progressive qui touche principalement les gar\u00e7ons et entra\u00eene une faiblesse musculaire, une perte de mobilit\u00e9 et un d\u00e9c\u00e8s pr\u00e9matur\u00e9. Les traitements actuels sont limit\u00e9s et beaucoup se concentrent sur la gestion des sympt\u00f4mes plut\u00f4t que sur l&#039;arr\u00eat ou l&#039;inversion de l&#039;\u00e9volution de la maladie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le lancement des essais cliniques de phase 2 pour le SAT-3247 constitue une \u00e9tape cruciale pour r\u00e9pondre \u00e0 ce besoin m\u00e9dical non satisfait. Selon Satellos, l&#039;objectif est d&#039;\u00e9valuer l&#039;innocuit\u00e9, la tol\u00e9rance et l&#039;efficacit\u00e9 du m\u00e9dicament aupr\u00e8s d&#039;un groupe plus large de patients atteints de DMD, suite aux r\u00e9sultats prometteurs de la phase 1.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"646\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg\" alt=\"\u00c9tude clinique de phase 2 Satellos SAT-3247\" class=\"wp-image-3735\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1024x646.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-300x189.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-768x485.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-666x420.jpg 666w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-150x95.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-696x439.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials.jpg 1057w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"whats-next-for-the-clinical-trial\">Quelle est la prochaine \u00e9tape pour l\u2019essai clinique ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos a indiqu\u00e9 finaliser les pr\u00e9paratifs pour l&#039;activation du site d&#039;essai et le recrutement des patients. L&#039;essai de phase 2 sera men\u00e9 \u00e0 l&#039;h\u00f4pital St. Vincent en Australie et inclura des hommes \u00e2g\u00e9s de 18 \u00e0 40 ans pr\u00e9sentant un diagnostic confirm\u00e9 de DMD. L&#039;\u00e9tude \u00e9valuera \u00e9galement les biomarqueurs de la r\u00e9g\u00e9n\u00e9ration musculaire et des am\u00e9liorations fonctionnelles, \u00e9tablissant potentiellement une nouvelle r\u00e9f\u00e9rence dans le traitement de la maladie de Duchenne.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le Dr Frank Gleeson, PDG de Satellos, a d\u00e9clar\u00e9 : \u00ab Nous sommes ravis de faire passer SAT-3247 en phase 2. Cette \u00e9tape refl\u00e8te notre engagement \u00e0 innover dans une approche de m\u00e9decine r\u00e9g\u00e9n\u00e9ratrice pour la maladie de Duchenne et \u00e0 am\u00e9liorer la vie des patients et des familles touch\u00e9s par cette maladie d\u00e9vastatrice. \u00bb<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"575\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg\" alt=\"\u00c9tude clinique de phase 2 Satellos SAT-3247\" class=\"wp-image-3736\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-1024x575.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-300x168.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-768x431.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-18x10.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-748x420.jpg 748w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-150x84.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1-696x391.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-CL-101-clinical-trials-1.jpg 1060w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Apprendre encore plus: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06867107\" target=\"_blank\" rel=\"noreferrer noopener\">\u00c9tude clinique de phase 2 Satellos SAT-3247\u00a0: NCT06867107<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"a-new-chapter-in-muscle-regeneration\">Un nouveau chapitre dans la r\u00e9g\u00e9n\u00e9ration musculaire<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Avec SAT-3247, Satellos repousse non seulement les limites de l&#039;innovation scientifique, mais apporte \u00e9galement de l&#039;espoir \u00e0 des milliers de familles \u00e0 travers le monde. En cas de succ\u00e8s, cette th\u00e9rapie pourrait ouvrir la voie \u00e0 une nouvelle classe de traitements r\u00e9g\u00e9n\u00e9ratifs pour les dystrophies musculaires et les affections apparent\u00e9es.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-my-son-participate-in-the-clinical-trial\">Comment mon fils peut-il participer \u00e0 l\u2019essai clinique de phase 2 SAT-3247\u00a0?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bien que Satellos ait annonc\u00e9 que les essais cliniques de phase 2 SAT-3247 seront men\u00e9s en Australie, nous recommandons aux patients atteints de DMD qui ont la possibilit\u00e9 de voyager en Australie et qui r\u00e9pondent aux crit\u00e8res de contacter Satellos en utilisant les coordonn\u00e9es ci-dessous.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nom<\/strong>: Satellos Affaires m\u00e9dicales\/D\u00e9veloppement clinique<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Num\u00e9ro de t\u00e9l\u00e9phone<\/strong>: +61 3 8736 1750<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: medicalinfo@satellos.com<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"685\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg\" alt=\"Comment mon fils peut-il participer \u00e0 l&#039;essai clinique de phase 2 SAT-3247\u00a0?\" class=\"wp-image-3827\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-1024x685.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-300x201.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-768x514.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-18x12.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-628x420.jpg 628w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-150x100.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info-696x466.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/04\/SAT-3247-Phase-2-Clinical-Trial-Contact-Info.jpg 1061w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"about-satellos-bioscience\">\u00c0 propos de Satellos Bioscience<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos Bioscience est une soci\u00e9t\u00e9 de biotechnologie torontoise qui se consacre \u00e0 la d\u00e9couverte et au d\u00e9veloppement de nouveaux m\u00e9dicaments r\u00e9g\u00e9n\u00e9ratifs pour les maladies li\u00e9es \u00e0 la d\u00e9g\u00e9n\u00e9rescence musculaire. Gr\u00e2ce \u00e0 sa plateforme exclusive MyoReGenX\u2122, Satellos vise \u00e0 exploiter la biologie des cellules souches musculaires pour inverser la progression des dystrophies musculaires.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a clinical-stage biotechnology company focused on developing regenerative therapies for muscle diseases, has announced at ClinicalTrials.Gov it is preparing to initiate a Phase 2 clinical study of its lead drug candidate, SAT-3247, targeting Duchenne Muscular Dystrophy (DMD). This marks a significant milestone in the company\u2019s mission to offer a transformative treatment for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3739,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,254,251,252,253],"class_list":["post-3729","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3729"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3739"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}